SCHEMBL289616

SCHEMBL289616

CCC/C=C/c1cccc(CC(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
LTB4R Q15722 2/20 0.47
LTB4R2 Q9NPC1 2/20 0.47
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
AKR1B1 P15121 1/20 0.43
PKM P14618 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
PAM P19021 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PLA2G4B P0C869 1/20 0.40
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PTGS1 P23219 1/20 0.39
AKR1C3 P42330 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289617 1.00 PPARG (0.47) PPARGPPARALTB4RLTB4R2ALDH1A1
SCHEMBL31585144 0.91 PPARA (0.46) PPARGPPARALTB4RLTB4R2ALDH1A1
SCHEMBL1716762 0.91 PPARA (0.46) PPARGPPARALTB4RLTB4R2ALDH1A1
SCHEMBL1628269 0.91 PPARA (0.46) PPARGPPARALTB4RLTB4R2ALDH1A1
SCHEMBL289471 0.84 CYP4F2 (0.56) PPARGPPARALTB4RLTB4R2ALDH1A1
SCHEMBL289470 0.84 CYP4F2 (0.56) PPARGPPARALTB4RLTB4R2ALDH1A1
SCHEMBL17678291 0.84 THRB (0.40) LTB4RLTB4R2ALDH1A1KDM4EAKR1B1
SCHEMBL4397024 0.84 AKR1B1 (0.56) PPARGPPARALTB4RLTB4R2ALDH1A1
SCHEMBL4397023 0.84 AKR1B1 (0.56) PPARGPPARALTB4RLTB4R2ALDH1A1
SCHEMBL4683487 0.83 PPARG (0.47) PPARGPPARALTB4RLTB4R2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11267779-B2 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis PROMETIC PHARMA SMT LIMITED (GB) 2022-03-08 US disclosed
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Liminal Biosciences Limited (GB) 2021-11-30 US disclosed
CN-107106526-B Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration 普罗米蒂克医药SMT有限公司 2021-05-28 CN disclosed
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION LIMINAL BIOSCIENCES LTD (GB) 2021-03-25 US disclosed
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION LIMINAL BIOSCIENCES LTD (GB) 2021-03-25 US disclosed
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof PROMETIC BIOSCIENCES, INC. (CA) 2021-01-07 US disclosed
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof PROMETIC BIOSCIENCES, INC. (CA) 2021-01-07 US disclosed
US-10869849-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration Liminal Biosciences Limited (GB) 2020-12-22 US disclosed
US-10869849-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration Liminal Biosciences Limited (GB) 2020-12-22 US disclosed
EP-3443957-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER LIMINAL BIOSCIENCES LTD (GB) 2020-11-25 EP disclosed
US-20130225683-A1 Compounds and Pharmaceutical Compositions for Uses in Diabetes PROMETIC BIOSCIENCES INC. (CA) 2013-08-29 US disclosed
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer PROMETIC BIOSCIENCES INC. (CA) 2013-08-22 US disclosed
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer PROMETIC BIOSCIENCES INC. (CA) 2013-08-22 US disclosed
WO-2012097427-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PROMETIC BIOSCIENCES INC. (CA) 2012-07-26 WO disclosed
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2012-04-12 US disclosed
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2012-04-12 US disclosed
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof PROMETIC PHARMA SMT LIMITED (GB) 2012-04-12 US disclosed
EP-2427416-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF ProMetic BioSciences Inc. (CA) 2012-03-14 EP disclosed
WO-2010127440-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC BIOSCIENCES INC. (CA) 2010-11-11 WO disclosed
WO-2010127440-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF PROMETIC BIOSCIENCES INC. (CA) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210085626-A1 SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION COL1A1, CCNH, COL2A1 PPARG 958/4885PPARA 2564/4885LTB4R 1657/4885
US-20130217645-A1 Compounds and Compositions for the Treatment of Cancer DCK, TOP2B, TOP2A PPARG 913/4885PPARA 2248/4885LTB4R 4712/4885
US-20210002202-A1 Substituted Aromatic Compounds and Pharmaceutical Uses Thereof TYR, PAH, REN PPARG 212/4885PPARA 276/4885LTB4R 1049/4885
US-10869849-B2 Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration COL1A1, CCNH, COL2A1 PPARG 958/4885PPARA 2564/4885LTB4R 1657/4885
US-11185521-B2 Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis ADIPOR1, ADIPOR2, FN1 PPARG 424/4885PPARA 544/4885LTB4R 1388/4885
US-20130225683-A1 Compounds and Pharmaceutical Compositions for Uses in Diabetes LIPG, PDK4, BCKDK PPARG 359/4885PPARA 439/4885LTB4R 1636/4885
US-20120088784-A1 Substituted Aromatic Compounds and Pharmaceutical Uses thereof TYR, PAH, REN PPARG 212/4885PPARA 276/4885LTB4R 1049/4885
US-11267779-B2 Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis PAH, HRH3, CFH PPARG 2346/4885PPARA 3243/4885LTB4R 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.